●
|
MEDI4736-MM-001: A
Phase Ib multicenter, open-label study to determine the recommended
dose and regimen of durvalumab either as monotherapy or in
combination with pomalidomide with or without low-dose
dexamethasone in patients with relapsed and refractory multiple
myeloma
|
●
|
MEDI4736-MM-003: A
Phase II, multicenter, open-label study to determine the safety and
efficacy for the combination of durvalumab and daratumumab in
patients with relapsed and refractory multiple
myeloma
|
●
|
MEDI4736-MM-005: A
Phase II, multicenter, single-arm study to determine the efficacy
for the combination of durvalumab plus daratumumab in patients with
relapsed and refractory multiple myeloma that have progressed while
on current treatment regimen containing
daratumumab
|
●
|
MEDI4736-NHL-001: A
Phase I/II, open-label, multi-center study to assess the safety and
tolerability of durvalumab as monotherapy and in combination
therapy in subjects with lymphoma or chronic lymphocytic leukaemia.
The only arm in this trial for which enrolment is suspended is the
arm with the durval REVLIMID® and rituximab
combination
|
●
|
MEDI4736-DLBCL-001:
A Phase II, open-label, multicenter study to evaluate the safety
and clinical activity of durvalumab in combination with rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) or
with lenalidomide plus R-CHOP (R2 CHOP) in patients with previously
untreated, high risk diffuse large
B Cell lymphoma
|
●
|
MEDI4736-MM-002: A
Phase Ib multicenter, open-label study to determine the recommended
dose and regimen of durvalumab in combination with lenalidomide
with and without low-dose dexamethasone in subjects with newly
diagnosed multiple myeloma
|
●
|
MEDI4736-MDS-001: A
randomised, multicenter, open-label, Phase II trial evaluating the
efficacy and safety of azacitidine subcutaneous in combination with
durvalumab in previously untreated subjects with higher-risk
myelodysplastic syndromes or in elderly (>= 65 Years) acute
myeloid leukaemia subjects not eligible for haematopoietic
stem cell
transplantation
|
●
|
CC-486-MDS-006: A
Phase II, international, multicenter, randomised, open-label,
parallel group to evaluate the efficacy and safety of CC-486 alone
in combination with durvalumab in subjects with myelodysplastic
syndromes who fail to achieve an objective response to treatment
with azacitidine for injection or
decitabine
|
Media
Relations
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
Nick
Stone
|
Respiratory,
Brilinta
|
+44 203
749 5716
|
Christer
Gruvris
|
Diabetes;
Autoimmunity, Neuroscience & Infection
|
+44 203
749 5711
|
US toll
free
|
|
+1 866
381 7277
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|